GSK Is First To Share Cancer Drug Patents With Poor Countries
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline to license its future cancer treatments for generic manufacturing in poor countries; access continues to be flagship issue for GSK's Witty, who also sits on recently formed UN access panel.
You may also be interested in...
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
AstraZeneca will reacquire Allergan's investigational IL-23 inhibitor brazikumab, and Nestle is to buy its GI drug Zenpep, which had nine-month revenue of $208m.
In joint complaint, the FTC and New York Attorney General allege scheme to block generic Daraprim and maintain exorbitant list price; they cite hundreds of emails the incarcerated Shkreli has exchanged with co-defendant in last six months.